熱門資訊> 正文
奥本海默以口服疫苗为重点，启动Vaxart以超越表现
2024-08-16 03:53
- Oppenheimer has initiated coverage of Vaxart (NASDAQ:VXRT) with an outperform rating, citing the company’s focus on oral vaccines.
- The investment bank said it's optimistic about Vaxart’s (VXRT) differentiated oral vaccine platform, particularly its vaccine candidates for norovirus and COVID-19. It noted that oral vaccines could offer better solutions for infectious diseases like norovirus.
- Oppenheimer sees the norovirus market as highly attractive and worth around $5B to $10B. It added that it doesn’t view a recent setback for an intramuscular norovirus vaccine being developed by HilleVax (HLVX) as negatively reading across to Vaxart’s (VXRT) program.
- The investment bank set its price target for the stock at $4.
More on Vaxart
- Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
- Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
- Vaxart Q2 2024 Earnings Preview
- Biggest stock movers today: ADBE, MSM, RH, and more
- Seeking Alpha’s Quant Rating on Vaxart
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
